Introduction and concluding remarks

European Urology

Volumn 38, Issue SUPPL. 1, 2000, Pages 1-6

  Chapple, C R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Drug therapy; Effectiveness; Efficacy; LUTS; Randomised controlled trials; Real life practice; Surgery; Tolerability; Triumph

Indexed keywords

ALFUZOSIN; DOXAZOSIN; SABAL EXTRACT; TAMSULOSIN; TERAZOSIN;

AGED; AGING; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERANCE; EASTERN EUROPE; HEALTH SURVEY; HUMAN; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; REPRODUCIBILITY; RISK ASSESSMENT; UNITED STATES; WESTERN EUROPE;

EID: 0033673933     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052396     Document Type: Conference Paper

References (30)

1. High prevalence of benign prostatic hypertrophy in the community
2. Randomized controlled trials for benign prostatic obstruction: Problems and pitfalls
3. Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: What are the relevant differences in randomised controlled trials?
4. Medical treatment modalities for lower urinary tract symptoms: What are the relevant differences in randomised controlled trials?
5. 1-Blocker therapy suggestive of benign prostatic obstruction: What are the relevant differences in randomised controlled trials?
6. Treatment satisfaction of patients with lower urinary tract symptoms: Randomised controlled trial vs. real life practice
7. How do symptoms indicative of BPH progress in real life practice? The UK experience
8. How are lower urinary tract symptoms managed in real life practice? The French experience
9. Surgery
10. A pilot study for a randomized controlled trial comparing the efficacy, safety and cost-effectiveness of surgical treatments of the prostate
11. The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia
12. The members of the committees: Recommendations of the international scientific committee: The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction
13. Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia
14. Medical therapy and quality of life
15. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia
16. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
17. Results of the PREDICT (Prospective European doxazosin and combination therapy) trial
18. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
19. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
20. Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia
21. A multicentric, placebo-controlled, double-blind clinical trial of β-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia
22. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia
23. Comparison of phytotherapy (Permixon ®) with finasteride in the treatment of benign prostatic hyperplasia: A randomized international study of 1,098 patients
24. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia
25. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does co-morbidity alter tolerability?
26. Tamsulosin: Real life clinical experience in 19,365 patients
27. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy
28. The pharmacovigilance of tamsulosin: Event data on 12,484 patients
29. The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14,772 patients
30. Using a large clinical database to assess the effectiveness of alfuzosin